ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 1

Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

October 16, 2024

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center, Christine Bestvina, MD, University of Chicago, Hatim Husain, MD, Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center, Julia K. Rotow, MD

This episode explores expert insights on the clinical use of osimertinib in the frontline setting for EGFR-mutated NSCLC, the impact of combining osimertinib with platinum-based chemotherapy on progression-free survival (PFS), and the significance of extending PFS by nearly 9 months in patients with advanced NSCLC who are not candidates for curative treatment.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

Now Viewing

EP. 1: Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

EP. 2: Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA

EP. 3: ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC

EP. 4: Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations

EP. 5: Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC

EP. 6: Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

EP. 7: Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01

EP. 8: Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies

EP. 9: Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC

EP. 10: Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC

EP. 11: Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd

EP. 12: Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

EP. 13: HERTHENA-Lung02 Trial: Exploring the Role of Patritumab Deruxtecan in Advanced EGFR-Mutant NSCLC

EP. 14: Navigating Treatment Choices: Clinically Meaningful Outcomes to Look for in HERTHENA-Lung02

EP. 15: Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC

Video content above is prompted by the following:

What has been your clinical experience with osimertinib in the frontline setting for EGFR-mutated NSCLC?

Please assess the impact of a 38% improvement in PFS with the combination of osimertinib and platinum-based chemotherapy vs osimertinib monotherapy in patients with advanced EGFR-mutated NSCLC.

From the perspective of a community oncologist, please share your insights on the meaningful benefit of extending PFS an additional 8.8-9.5 months among untreated patients with advanced NSCLC, not amenable to curative resection or radiotherapy.